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The 2009 Montagna Symposium, 
Genetic–Epigenetic Basis of Skin Diseases,* 
was attended by approximately 100 
scientists, clinicians, residents, stu-
dents, industrial representatives, and 
representatives from the National 
Institutes of Health. The program was 
held over three days and included five 
sessions: (i) “Genetic Control of Skin 
Morphogenesis,” (ii) “Epigenetics, 
Skin Development, and Diseases,” 
(iii) “Developmental Genetics and 
Epigenetics,” (iv) “Genetic Basis of 
Disease and Genomic Approaches,” 
and (v) “Novel Opportunities for 
Therapies for Genetic Diseases.”
An important theme was compart-
ments of the skin, both epidermis and 
dermis, and how regulation of gene 
expression is achieved by both genetic 
and epigenetic mechanisms. The ses-
sions were ordered to reflect increas-
ing complexity, beginning with the 
molecular controls of gene regulation, 
working through the cellular conse-
quences of genetic changes (i.e., what 
happens when these processes are 
disturbed in different diseases), and 
finally addressing how our knowledge 
of the genetic basis of disease can be 
used to generate novel therapeutic 
strategies.
In addition to talks by invited speak-
ers, several short talks were selected 
from abstracts. Ample discussion time 
was included after each talk, and on the 
last day the attendees broke into small 
groups to discuss specific research 
questions and future research priorities. 
The relatively small size of the meeting 
facilitated interaction among attendees.
The meeting opened with a keynote 
address by Howard Chang (Stanford 
University), who gave an overview 
of noncoding RNAs and epigenetics. 
Dr. Chang explained that while both 
genetic and epigenetic changes in 
DNA are heritable, epigenetic changes 
are distinct in that they are reversible 
and do not involve sequence changes 
in the DNA itself. Using the hox locus 
as an example, he described how 
long noncoding RNAs are an ancient, 
conserved mechanism of DNA regu-
lation involved in positional identity 
of the dermis during skin morphogen-
esis, with a potentially broader role in 
disease.
The first full day of the meet-
ing began with the session enti-
tled “Genetic Control of Skin 
Morphogenesis.” The goal of this ses-
sion was to explore the role of devel-
opmental signaling pathways and 
their downstream effectors (transcrip-
tion factors) in normal and abnormal 
skin growth. Sarah Millar (University 
of Pennsylvania) and Andrezj Dlugosz 
(University of Michigan) presented 
results of a study in which the genetic 
control of hair follicle formation was 
disrupted. They revealed that if wnt 
or shh signaling is perturbed, both 
the numbers and the morphogen-
esis of hair follicles and other skin 
appendages, such as teeth, are per-
turbed and can be directed toward 
tumor formation. This was followed 
by three talks discussing the roles of 
various transcription factors in skin 
and hair development. Carol Trempus 
(National Institute of Environmental 
Health Sciences, North Carolina) 
reported that if the T-box transcription 
factor Tbx1 is increased, tumor forma-
tion is inhibited. Arup Indra (Oregon 
State University) discussed the neces-
sity of balance of the chicken oval-
bumin upstream promoter (COUP) 
transcription factor CTIP-2 during 
development, showing that mis-
expression results in barrier function 
defects. Maranke Koster (University 
of Colorado, Denver) demonstrated 
that an imbalance of the p63 isoforms 
during development results in ecto-
dermal dysplasia. Later, Benjamin 
Yu (University of California, San 
Diego) and Laura Hansen (Creighton 
University) discussed the regulation 
of skin phenotypes by varying the lev-
els of receptors and/or ligands for the 
receptors, with an emphasis on fibro-
blast growth factor– and epidermal 
growth factor–dependent signaling.
In the second scientific session, 
“Epigenetics, Skin Development, 
and Diseases,” Rui Yi (University 
of Colorado) and Robert Lavker 
(Northwestern University) showed how 
varying levels of microRNAs can regu-
late gene expression in the developing 
epidermis. Radhika Atit (Case Western 
Reserve University) then showed that 
wnt signaling can affect the develop-
mental programs of the skin in different 
body sites. Mangalam Subramanian 
(Texas Women’s University) discussed 
histone acetylation and deacetyla-
tion in the regulation of global DNA 
repair. Finally, Colin Jamora (University 
of California, San Diego) described 
how perturbation of Snail-mediated 
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cross-talk between epithelial cells and 
leukocytes can lead to skin carcinoma.
The third scientific session, 
“Developmental Genetics and 
Epigenetics,” began with a general 
overview of the genetic basis for pig-
mentary skin diseases by Vincent 
Hearing (National Cancer Institute), 
who showed that many of the genes 
controlling melanogenesis in skin 
development result in pigmentary dis-
ease when mutated. Michael Marks 
(University of Pennsylvania) discussed 
the regulation of melanosome biogen-
esis and how disruption of trafficking 
results in Hemansky–Pudlak syndrome. 
Maite Huarte (Harvard Medical School) 
identified a relationship between large 
intergenic noncoding RNAs and p21 
misregulation in cancer. Next, Elena 
Ezhkova (Rockefeller University) and 
Richard Eckert (University of Maryland) 
discussed epigenetic regulation of skin 
stem cells and keratinocyte survival, 
with a particular emphasis on the role 
of the polycomb family of proteins. 
Maria Morasso (National Institute of 
Arthritis and Musculoskeletal and Skin 
Diseases (NIAMS)) discussed the role 
of DLX3 in the morphogenesis of hair 
follicles and other epidermal append-
ages and the role of DLX3 in differ-
ent ectodermal dysplasia phenotypes. 
Stephanie Shirley (University of Texas, 
MD Anderson) reported that UV light 
increased Snail family members, result-
ing in melanoma. Finally, Michael 
Fessing (University of Bradford, UK) 
presented emerging work on the three-
dimensional architecture of DNA into 
“chromosome territories” and discussed 
how this higher-order organization can 
add an additional level of control to 
gene expression.
In the session entitled “Genetic Basis 
of Disease and Genomic Approaches,” 
Irwin McLean (University of Dundee) 
described the genetic basis of atopic 
dermatitis and the role of filaggrin 
mutations in this common disease. 
He then presented new findings illus-
trating common genetic associations 
between eczema and asthma. Anne 
Bowcock (Washington University, 
St Louis) followed, discussing the 
complex genetic basis of psoriasis and 
outlining several innovative systems 
biology approaches for integrating 
gene expression data on copy number 
variants with the analysis candidate 
loci that arise from genome-wide asso-
ciation studies. Chrisophe Cataisson 
(National Cancer Institute) discussed 
the genetic regulation of tumor for-
mation. Christina de Guzman Strong 
(National Human Genome Research 
Institute (NHGRI)) described a com-
parative genetic approach to disease 
gene discovery by studying con-
served elements across species, with 
an emphasis on the epidermal differ-
entiation complex genes. Later, Allan 
Balmain (University of California, San 
Francisco) reported on several mouse 
models of skin cancer and how the 
power of mouse genetics could be 
used to discover genetic susceptibil-
ity. Rebecca Morris (Hormel Institute, 
Minnesota) reported that BMP5, a can-
didate stem cell regulatory gene that 
she identified from a screen for quan-
titative trait loci, affects tumor sus-
ceptibility. Shirley Russell (Vanderbilt 
University) then discussed keloids 
as a model of epigenetically altered 
wound healing. Carl Baker (NIAMS) 
ended the session with information 
about NIAMS funding for genetic and 
epigenetic research.
In the final session, on translational 
research—“Novel Opportunities for 
Therapies for Genetic Diseases”—Ervin 
Epstein (Children’s Hospital Research 
Institute, Oakland, CA) outlined the 
potential for novel therapies in the 
shh pathway for basal cell carcinoma 
(BCC), including mouse models of the 
disease and what these have taught us 
about treating patients with BCC. Julie 
Segre (NHGRI) discussed her new 
studies determining the diversity of 
the skin microbiome on various body 
sites using global genomic approach-
es. Two industrial scientists working 
on skin-related diseases spoke next. 
Patrick Iversen (AVI Biopharma) dis-
cussed antisense-based therapies for 
both genetic and acquired inflam-
matory diseases, and Roger Kaspar 
(TransDerm) discussed the develop-
ment of small interfering RNA skin 
therapeutics for targeting dominant 
mutations in an allele-specific manner 
using topical delivery. Al Klingelhutz 
(University of Iowa) ended the session 
with a description of a human model 
for studying telomere shortening in 
aging skin and a model for dyskeratosis 
congenita.
2009 SiD eugene m. Farber travel 
Awards for Young investigators
As in the past, nine young investigators 
attended the Montagna Symposium 
thanks to a generous donation from the 
Eugene M Farber family through the 
Society for Investigative Dermatology:
Caitlin Cloud
Department of Anatomy and Cell 
Biology and Department of Pathology, 
University of Iowa, Iowa City, IA
elena ezhkova, phD
Mammalian Cell Biology  
and Development,  
Howard Hughes Medical Institute, 
Rockefeller University, New York, NY
géraldine guasch, phD
Division of Developmental Biology, 
Cincinnati Children’s Hospital 
Medical Center, Cincinnati, OH
mikael Langner, mD
Department of Dermatology, 
University of California, San 
Francisco, San Francisco, CA
Latondra Lawrence
Department of Biology,  
Texas Woman’s University, Denton, TX
Stephanie Harkey Shirley, phD
Department of Carcinogenesis, 
University of Texas MD Anderson 
Cancer Center, Smithville, TX
mangalam Subramanian
Department of Biology,  
Texas Woman’s University, Denton, TX
Kathleen tober, phD
Department of Pathology,  
The Ohio State University,  
Columbus, OH
Valerie Verstraeten, mD
Department of Medicine,  
Brigham and Women’s Hospital, 
Harvard University, Boston, MA 
and Department of Dermatology, 
University of Maastricht,  
The Netherlands
Bickenbach et al.
Montagna Symposium 2009: Genetic–Epigenetic Basis of Skin Diseases
 www.jidonline.org 1201
ACKNOWLEDGMENTS
•  National Institute of Arthritis, Musculoskeletal and 
Skin Diseases (5 R13 AR009431-43)
•  The Eugene M. Farber family
•  Amgen, Bristol-Myers Squibb, Centocor Ortho 
Biotech, the Epidermolysis Bullosa Medical 
Research Foundation, Johnson & Johnson 
Consumer & Personal Products Worldwide, 
the Proctor & Gamble Company, Valeant 
Pharmaceuticals, the National Psoriasis Foundation, 
Astellas, Graceway Pharmaceuticals, LLC, the 
Orentreich Foundation for the Advancement 
of Science, Inc., Taisho Pharmaceuticals 
Co., Ltd., and the Oregon Health & Science 
University Department of Dermatology.
*The 2009 Montagna Symposium, “Genetic–
Epigenetic Basis of Skin Diseases,” was 
held at the Salishan Resort, Gleneden 
Beach, Oregon, USA, 8–12 October 2009. 
Information about content and support of past 
symposia and the next Montagna Symposium 
on the Biology of Skin can be found at http://www.
montagnasymposium.org.
montagna 2010
"Small Molecules: Skin as the First Line of Defense"
7–11 october 2010, Salishan resort, gleneden Beach, oregon
Program Chair: Richard Gallo, MD, PhD
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